Why the study?
Do synthetic peptides corresponding to predicted immunogenic sites on human rhinovirus type 2 elicit neutralizing antibodies?
Do synthetic peptides corresponding to predicted immunogenic sites on human rhinovirus type 2 elicit neutralizing antibodies?
A synthetic peptide covering the NIm-II epitope on VP2 of human rhinovirus type 2 can successfully elicit neutralizing antibodies in a preclinical model.
Supports peptide vaccine exploration for rhinovirus; leaves open human translation and efficacy.
Synthetic peptides corresponding to six predicted immunogenic sites on human rhinovirus type 2 (HRV2) have been tested for their reactivity with an anti-virion antibody and for their ability to elicit neutralizing antibody. Four of the peptides reacted with HRV2 antiserum in an indirect ELISA. Rabbit antisera produced to three of these four peptides, one each from VP1, VP2 and VP3, reacted with the virus in an indirect ELISA and with the corresponding proteins by Western blotting. Furthermore, antiserum to one of the peptides, designed to cover the neutralization epitope NIm-II on VP2, not only reacted well in a sandwich ELISA and in an immunoprecipitation test but also neutralized virus infectivity.
No takes yet. Share an insight, caveat, or question.
Francis et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: